Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

Androgen receptor (AR) antagonists, such as enzalutamide, have had a major impact on the treatment of metastatic castration-resistant prostate cancer (CRPC). However, even with the advent of AR antagonist therapies, patients continue to develop resistance, and new strategies to combat continued AR s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kregel, Steven, Wang, Chao, Han, Xin, Xiao, Lanbo, Fernandez-Salas, Ester, Bawa, Pushpinder, McCollum, Brooke L., Wilder-Romans, Kari, Apel, Ingrid J., Cao, Xuhong, Speers, Corey, Wang, Shaomeng, Chinnaiyan, Arul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957805/
https://www.ncbi.nlm.nih.gov/pubmed/31931431
http://dx.doi.org/10.1016/j.neo.2019.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957805/
https://www.ncbi.nlm.nih.gov/pubmed/31931431
http://dx.doi.org/10.1016/j.neo.2019.12.003

Ejemplares similares